High-dose desvenlafaxine in outpatients with major depressive disorder
JM Ferguson, KA Tourian, GR Rosas - CNS spectrums, 2012 - cambridge.org
ObjectiveThis study investigated the safety and efficacy of long-term treatment with high-
dose desvenlafaxine (administered as desvenlafaxine succinate) in major depressive …
dose desvenlafaxine (administered as desvenlafaxine succinate) in major depressive …
[HTML][HTML] A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder
KA Tourian, B Pitrosky, SK Padmanabhan… - The Primary Care …, 2011 - psychiatrist.com
Background: The primary objective was to evaluate the long-term safety of desvenlafaxine
(administered as desvenlafaxine succinate) during open-label treatment in adult outpatients …
(administered as desvenlafaxine succinate) during open-label treatment in adult outpatients …
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder
AD Feiger, KA Tourian, GR Rosas… - CNS spectrums, 2009 - cambridge.org
Introduction: This research compares the efficacy and safety of desvenlafaxine
(administered as desvenlafaxine succinate) versus placebo in treating major depressive …
(administered as desvenlafaxine succinate) versus placebo in treating major depressive …
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
MR Liebowitz, AL Manley… - … medical research and …, 2008 - Taylor & Francis
Objective: To assess the efficacy, safety, and tolerability of 50-and 100-mg/day doses of
desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine …
desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine …
A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major …
MR Liebowitz, KA Tourian, E Hwang, L Mele… - BMC psychiatry, 2013 - Springer
Background In an effort to establish the lowest effective dose of desvenlafaxine
(administered as desvenlafaxine succinate), we assessed the efficacy, safety, and …
(administered as desvenlafaxine succinate), we assessed the efficacy, safety, and …
[HTML][HTML] Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials
MR Liebowitz, KA Tourian - The Primary Care Companion …, 2010 - legacy.psychiatrist.com
Objective: Desvenlafaxine is the third serotonin-norepinephrine reuptake inhibitor (SNRI)
approved by the US Food and Drug Administration for major depressive disorder (MDD) …
approved by the US Food and Drug Administration for major depressive disorder (MDD) …
Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline
D Mosca, M Zhang, R Prieto… - Journal of Clinical …, 2017 - journals.lww.com
Purpose This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50
and 100 mg versus placebo across age groups and severity of depression at baseline in …
and 100 mg versus placebo across age groups and severity of depression at baseline in …
Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients
N Iwata, KA Tourian, E Hwang, L Mele… - Journal of Psychiatric …, 2013 - journals.lww.com
Background. This study evaluated the efficacy and safety of low-dose desvenlafaxine
(administered as desvenlafaxine succinate) in treating major depressive disorder (MDD) …
(administered as desvenlafaxine succinate) in treating major depressive disorder (MDD) …
An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder
AH Clayton, SG Kornstein, G Rosas, C Guico-Pabia… - CNS …, 2009 - cambridge.org
Introduction: The safety and tolerability profiles of antidepressants can often influence the
treatment choices of clinicians treating major depressive disorder. The purpose of this …
treatment choices of clinicians treating major depressive disorder. The purpose of this …
An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder
JL Carrasco, SG Kornstein, RS McIntyre… - International Clinical …, 2016 - journals.lww.com
The chronic course of major depressive disorder (MDD) often impedes the ability of patients
to achieve full remission. Return of full functioning is a critical goal of antidepressant …
to achieve full remission. Return of full functioning is a critical goal of antidepressant …